Landos Biopharma Secures $60M Financing, Continues BT-11 Development for IBD

Landos Biopharma Secures $60M Financing, Continues BT-11 Development for IBD
Landos Biopharma’s investigational BT-11 therapy for inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD), is continuing testing in Phase 2 clinical trials — some of which are, or soon will be, enrolling participants. BT-11 is a small molecule, given orally, that binds to a protein called LANCL2, leading to a potent anti-inflammatory response. Importantly, the action of BT-11 is restricted to the gut. Now, Landos has secured $60 million in new funding that will support the BT-11 clinical program, the company announced. “This financing is an important part of our strategy to advance lead product BT-11 into global Phase 2 clinical trials for ulcerative colitis and Crohn’s disease,” Josep Bassaganya-Riera, president and CEO of Landos, said in a press release. “There is an unmet clinical need for new therapies for complex diseases such as Inflammatory Bowel Disease. We are pleased that our investors share Landos’ mission of accelerating drug development and serving the unmet needs of millions of patients living with these widespread and debilitating conditions,” he added. Preclinical (in the lab) studies showed that treating four mouse models of inflammatory bowel disease with BT-11 decreased inflammation in the gut by 90%. Further, in other mouse models, BT-11 showed better results than other, more expensive IBD medicines. The researchers said BT-11 outperformed anti-TNF antibodies
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *